Neurology - Page 2

Registered on ClinicalTrials

Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)

The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

The value of mitochondrial dysfunction in stabilization

The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)

The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

The value of mitochondrial dysfunction in stabilization

Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol

Authors:
Z. A. GONCHAROVA, I. V. CHERNIKOVA, V. A. NAZAROVA, V. V. TOLMACHEVA, K. G. OVSEPYAN
Rostov State Medical University of the Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis

Author:
V.V. ZAKHAROV, N.V. VAKHNINA
Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov” of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis

Authors:
I.A. VOZNYUK^1,2, S.V. KOLOMETSEV^2,3, E.M. MOROZOVA¹

Arterial hypertension and cognitive disorders. The gaze of a neurologist

Author:
A.I. FEDIN

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Approaches to pharmacotherapy of vascular moderate cognitive disorders in patients of various age groups

Authors:
V.V. ZAKHAROV¹, A.I. FEDIN², E.A. MKHITARYAN^2,³

Features of pharmacotherapy of vascular cognitive impairment in elderly people

Author:
A.N. BOGOLEPOVA^1,²

¹N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia;
²Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia, Moscow, Russia

Increasing the efficiency of pharmacotherapy in comorbide patients with chronic brain ischemia on an outpatient basis

Authors:
T.L. VISILO¹, E.G. AREFIEV²

The possibilities of multimodal neuroprotection in patients with chronic brain ischemia against the background of arterial hypertension and atherosclerosis

Authors:
I.A. GRIBACHEV, T.F. POPOVA, E.V. PETROVA, A.V. ZVONKOVA

FSBEI in Novosibirsk State Medical University of the Ministry of Health of Russia

Oxidative stress in the pathogenesis of cerebral stroke and its correction

Authors:
M.Yu. MARTYNOV^1,2, M.V. ZHURAVLEVA^3.4, N.S. VASYUKOVA⁵, E.V. KUZNETSOVA⁶, T.R. KAMENEVA⁷

The results of clinical studies of the effectiveness and safety of the use of ethylmethylhydroxypyridine of succinate in patients with chronic brain ischemia

Authors:
M.V. ZHURAVLEVA^1,2, P.R. KAMCHATNOV³, N.S. VASYUKOVA⁴, V.V. ARKHIPOV¹, E.V. KUZNETSOVA⁵, T.R. KAMENEVA⁶, S.Yu. SEREBROVA^1,2

The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)

Authors:
V.V. ZAKHAROV¹, O.N. TKACHEV^2,³, E.A. MKHITARYAN^2,³, A.I. FEDIN²

Safety Mexidol® (ethylmethylhydroxypyridine of succinate) in adult patients of different age groups

Authors:
E.A. USHKALOVA¹, S.K. ZYRYANOV^1,2, O.I. BUTRANOVA¹

¹Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia”
²State Budgetary Healthcare Institution “City Clinical Hospital No. 24 of the Moscow City Health Department”

Hypoxia and oxidant stress with cerebrovascular failure and effective ways to correct them

Authors:
E.I. CHUKANOVA, A.S. CHUKANOVA, D.M. RODIONOVA

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Cognitive disorders diagnostic algorithm in outpatient practice

Authors:
E.A. MKHITARYAN, M.A. ATTIC

Study of the effectiveness and safety of the sequential use of Mexidol and Mexidol Forte 250 in the treatment of patients with acute ischemic stroke

Authors:
S.M. KARPOV¹, M.Yu. MOROZOVA², K.A. MURAVYEV², I.A. VYSHLOVA¹, F.S. KANTEMIROVA³

COVID-19-SSSOCIETED STROKE

Authors:

IA Shchukin, 1 MS Fidler, 1 IA Koltsov, 1 and A. Yu. Suvorov2

Translated from Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova, Vol. 121, No. 12, Iss. 2, pp. 69–76,
December, 2021. Original article submitted December 20, 2021. Accepted December 22, 2021.

Publication location:
Neuroscience and Behavioral Physiology, Vol. 52, No. 5, June 2022

« 1 2 3 4 … 7 »